ScholarIQanswers from OpenAlex
Tampere University
InstitutionResearch output, impact & collaborations
Tampere University is a institution indexed in ScholarIQ from OpenAlex.
What is known about Tampere University?
ScholarIQrecord summary
Tampere University is a research organisation in Tampere, FI. OpenAlex records 56,241 works and 3,031,927 citations for it. 8,334 researchers list it as their most recent affiliation.
How many works does Tampere University have?
ScholarIQindexed works
Tampere University has 56,241 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Tampere University have?
ScholarIQcitation count
Tampere University has 3,031,927 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Tampere University?
ScholarIQresearcher count
Tampere University has 8,334 researchers in the ScholarIQ index.
What is the average h-index at Tampere University?
ScholarIQavg h-index
Tampere University has an average h-index of 60.6 in OpenAlex.
What is the ROR of Tampere University?
ScholarIQror
The ROR for Tampere University is on the source record.
What is the OpenAlex record for Tampere University?
ScholarIQopenalex
The OpenAlex for Tampere University is on the source record.
Who are the most-cited researchers behind Tampere University?
ScholarIQtop researchers by citations
What are the most-cited papers on Tampere University?
ScholarIQmost cited works
Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and Finland
Paul Lichtenstein, Niels V. Holm, Pia K. Verkasalo, Anastasia Iliadou, Jaakko Kaprio, Markku Koskenvuo, Eero Pukkala, Axel Skytthe, Kari Hemminki
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder, Jonas Hugosson, Monique J. Roobol, Teuvo L.J. Tammela, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Hans Lilja, Marco Zappa, Louis Denis, Franz Recker, Antonio Berenguer, Liisa Määttänen, Chris H. Bangma, Gunnar Aus, Arnauld Villers, Xavier Rebillard, Theodorus van der Kwast, B. G. Blijenberg, Sue M. Moss, Harry J. de Koning, Anssi Auvinen
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta, Rosíres Pereira de Andrade, Kevin A. Ault, Anna R. Giuliano, Cosette M. Wheeler, Laura A. Koutsky, Christian Malm, Matti Lehtinen, Finn Egil Skjeldestad, Sven-Eric Olsson, Margareta Steinwall, Darron R. Brown, Robert J. Kurman, Brigitte M. Ronnett, Mark H. Stoler, Alex Ferenczy, Diane M. Harper, Gretchen Tamms, Jimmy Yu, Lisa Lupinacci, Radha Railkar, Frank J. Taddeo, Kathrin U. Jansen, Mark T. Esser, Heather L. Sings, Alfred J. Saah, Eliav Barr
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schröder, Jonas Hugosson, Monique J. Roobol, Teuvo L.J. Tammela, Marco Zappa, Vera Nelen, Maciej Kwiatkowski, M. Luján, Liisa Määttänen, Hans Lilja, Louis Denis, Franz Recker, Álvaro Páez, Chris H. Bangma, Sigrid Carlsson, Donella Puliti, Arnauld Villers, Xavier Rébillard, Matti Hakama, Ulf‐Håkan Stenman, Paula Kujala, Kimmo Taari, Gunnar Aus, Andreas Huber, Theodorus van der Kwast, Ron H. N. van Schaik, Harry J. de Koning, Sue Moss, Anssi Auvinen
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schröder, Jonas Hugosson, Monique J. Roobol, Teuvo L.J. Tammela, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, M. Luján, Hans Lilja, Marco Zappa, Louis Denis, Franz Recker, Álvaro Páez, Liisa Määttänen, Chris H. Bangma, Gunnar Aus, Sigrid Carlsson, Arnauld Villers, Xavier Rébillard, Theodorus van der Kwast, Paula Kujala, B. G. Blijenberg, Ulf‐Håkan Stenman, Andreas Huber, Kimmo Taari, M Hakama, Sue Moss, Harry J. de Koning, Anssi Auvinen
How much of the research on Tampere University is open access?
ScholarIQopen access share
75%OPEN ACCESS